FDA Clears Investigational New Drug Application to Test sCAR-T Therapy for Autoimmune Conditions
The FDA has cleared Calibr‑Skaggs Institute’s investigational new drug application to test its switchable CAR‑T therapy, CLBR001 + SWI019, in a phase 1 trial for autoimmune diseases. The study will enroll patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis, aiming to demonstrate safety without the lymphodepletion chemotherapy required by traditional CAR‑T. The therapy pairs a engineered T‑cell with a protein switch to target CD19‑positive B cells, a design that previously showed higher expansion and reduced cytokine‑release risks in B‑cell cancers. Recruitment is set to begin soon under NCT06913608.
Health‑coverage Decisions in Retirement Can Shape when and How Federal Retirees Tap Their Money
Federal retirees must navigate FEHB coverage abroad, the eight‑month Medicare Part B special enrollment period, and decisions about their Thrift Savings Plan. Overseas, some FEHB plans like Blue Cross Blue Shield process claims locally, while others require out‑of‑pocket payment and reimbursement,...
Bioanalytical Method Validation for Biomarkers
The U.S. Food and Drug Administration issued final Level 2 guidance (Docket FDA‑2017‑D‑6821) on bioanalytical method validation for biomarkers. It outlines the evidentiary standards for measuring biomarker concentrations in clinical trials and non‑clinical studies. The guidance applies to IND, NDA, BLA, ANDA,...
Alpheus Medical Advances to Phase 2b Testing of Experimental Brain Cancer Therapy
Alpheus Medical has enrolled 10 patients in a Phase 2b randomized trial of its Porphyrin Metabolite Activation (PoMA) therapy for newly diagnosed glioblastoma. PoMA uses a tumor‑selective drug activated by low‑intensity diffuse ultrasound to treat the entire affected brain hemisphere,...
Hospital M&A Rebounds After 2025 Lull
Hospital and health‑system M&A rebounded in Q1 2026, with 22 announced deals—the highest first‑quarter total in six years. The quarter’s transacted revenue hit $14.5 billion, buoyed by several mega‑mergers exceeding $1 billion in annual revenue. Divestitures dominated, accounting for 15 of the...
Bayer Pharma Executive Predicts US-Europe Price Spreads Will Narrow
Bayer's chief operating officer for pharmaceuticals warned that the long‑standing price gap between the United States and European markets will shrink sharply. He attributes the change to the Trump administration's push for “most‑favored‑nation” (MFN) pricing agreements, which compel manufacturers to...
UFC Renews Partnership With HSS to Boost Fighter Recovery
UFC has renewed its partnership with Hospital for Special Surgery (HSS) under a new multiyear agreement, extending the collaboration that began in 2017. HSS will maintain its integrated role at the UFC Performance Institute, adding an enhanced presence at the...
What General Atlantic’s $3B TEAM Bet Says About Home-Based Care’s Evolution
General Atlantic acquired home‑care platform TEAM Services for roughly $3 billion, a deal reported at a 10‑times multiple. The purchase highlights a shift toward tech‑enabled, infrastructure‑heavy providers that blend direct care with payroll and Medicaid financial‑management services. TEAM’s portfolio, bolstered by...
Waitlist Drops, but 717 Still Waiting for Gynaecology Care in Hawke’s Bay
Health New Zealand reports 717 patients still awaiting gynecology care in Hawke’s Bay, down from over 900 last year, as weekly new consultations rise to 39. Waiting periods over a year have fallen to 113, yet many women with chronic conditions...
Active HIMSS Communities Drive Healthcare Industry Progress
HIMSS’s global community of committees, workgroups and task forces, led by senior thought leaders, is translating strategic plans into measurable change across the health‑care sector. By pooling expertise in business intelligence, operations and workforce development, the organization accelerates digital transformation,...
HIMSS Attendance Makes for Conversation, Collaboration, Commitment
The annual HIMSS Global Conference continues to serve as a catalyst for face‑to‑face dialogue among health‑IT professionals. Tammy Kwiatkoski notes that 75% of HIMSS members participate in one of its 22 specialized communities, underscoring deep engagement. Attendees cite the event’s...
New Research Sheds Light on U.S. State Variations in Longevity Improvements
A new study analyzing CDC mortality data reveals that gains in U.S. life expectancy have diverged sharply across states over the past decade. While states such as Massachusetts and Colorado have added more than two years to average longevity since...
State Associations Urge CMS to Forgo Potential National Hospice Enrollment Moratorium
A coalition of state hospice associations—including Florida, North Carolina, and South Carolina—has written to CMS urging it to reject a proposed national moratorium on new hospice provider enrollments. They argue that a blanket freeze would restrict legitimate hospice growth in...
Replimune’s Advanced Melanoma Drug Rebuffed by FDA for Second Time
Replimune’s oncolytic immunotherapy RP1, aimed at unresectable advanced cutaneous melanoma, was rejected by the FDA for a second time on April 6, 2026. The agency’s complete response letter said the data, derived from a single‑arm trial, were insufficient to demonstrate substantial effectiveness,...
A Multi-Society Effort Is Driving Imaging Interoperability Across Healthcare
Digital pathology is expanding rapidly, but labs face a critical hurdle: making whole‑slide images interoperable across vendors and institutions. A joint webinar by the Digital Pathology Association, the College of American Pathologists, and the Society for Imaging Informatics in Medicine...
Health Care Roundup: Market Talk
AstraZeneca's Q1 outlook hints at higher spending to launch camizestrant for breast cancer and baxdrostat for hypertension, while Farxiga inventory reductions could pressure sales as generics enter the U.S. market. Analysts also expect strong contributions from oncology staples Imfinzi, Tagrisso...
BMS and Oxford BioTherapeutics Join Forces in TCE Discovery Pact
Bristol Myers Squibb has entered a discovery partnership with Oxford BioTherapeutics to develop T‑cell engager (TCE) therapies for solid tumours. BMS will pay an undisclosed upfront fee to access OBT’s OGAP‑Verify platform, while OBT will design and deliver pre‑clinical candidates....
PVL After TTVR Linked to Much Lower Survival Rate, Fewer Clinical Benefits
A new analysis of the TRIPLACE registry shows that paravalvular leak (PVL) after transcatheter tricuspid valve replacement (TTVR) dramatically worsens outcomes. Moderate or greater PVL was present in 6.1% of nearly 400 patients and drove one‑year all‑cause mortality to 39.7%,...
Babies Born to Lower-Income Families Face Worse Birth Outcomes
A new study of 380,000 U.S. births from 2012‑2022 links family income directly to newborn health. Mothers below 200% of the federal poverty line experienced higher rates of preterm delivery and low birthweight, with the low‑birthweight gap widening sharply over...
Evolving Approaches to CKD-MBD Address Cardiovascular and Fracture Risk
A new review from the University of Florida highlights that patients with chronic kidney disease (CKD) and end‑stage kidney disease (ESKD) continue to suffer high cardiovascular and fracture mortality despite traditional phosphate‑focused treatment. The authors argue that targeting novel pathways...
DHA Offers $300M for Health IT Deployment Support
The Defense Health Agency (DHA) has issued an indefinite‑delivery, indefinite‑quantity (IDIQ) solicitation for up to $300 million to support global deployments of its electronic health‑record platform MHS GENESIS and associated medical‑device integrations. The one‑year contract, with possible annual extensions, seeks commercial services...
Other News to Note for April 10, 2026
BioWorld’s April 10 briefing highlights three notable developments. Jiangsu and Shanghai Hengrui have patented novel Nav1.8 sodium‑channel blockers, a class of compounds with potential for pain and inflammatory disease therapies. New hematopoietic stem‑cell research links chronic inflammation to early‑stage leukemia, deepening...
CDER Manual of Policies & Procedures | MAPP
The FDA’s Center for Drug Evaluation and Research (CDER) has posted ten updated Manual of Policies and Procedures (MAPPs) covering drug safety, generic drug review, new drug assessment, and public outreach. The revisions, dated between July 2025 and January 2026,...
2026 Future Leaders Awards: Final Entry Deadline Approaching
The 2026 Future Leaders Awards are entering their final entry phase, with submissions due by 11:59 pm CDT on April 15, 2026. The program spotlights high‑performing employees 40 years or younger who are shaping home health, home care, and related sectors. Winners receive press‑release recognition,...
China Biotech’s CRISPR Therapy Suggests US Drugmakers Will Face Competition
A Chinese biotech firm used CRISPR‑Cas9 to edit blood stem cells in five beta thalassemia patients, eliminating their need for regular transfusions. The ex‑vivo therapy reactivates fetal hemoglobin and showed durable engraftment with no serious adverse events over a year...
Using Menstrual Blood-Derived Particles to Treat Osteoarthritis
Lithuanian researchers have demonstrated that extracellular vesicles (EVs) harvested from menstrual‑blood‑derived mesenchymal stromal cells can stimulate cartilage regeneration in vitro, offering a cell‑free therapy for osteoarthritis. The EVs improved chondrocyte function and extracellular matrix synthesis even in cartilage cells taken...
Autonomous Coding Tech Boosts Revenue 5.1% at Mercyhealth
Mercyhealth, a 200‑location health system in Wisconsin and Illinois, deployed Arintra’s autonomous coding platform within its Epic EHR to address a surge to over 130,000 monthly charts. The AI‑driven tool automates routine coding, freeing coders for complex, high‑value work while...
Apple Unveiled a New High-End Market Opportunity This Week
Apple’s Studio Display XDR earned FDA clearance for its Medical Imaging Calibration feature, opening a new niche in the medical‑device market. The $2,899 calibrated display can replace traditional radiology workstations that cost $15,000 or more, offering a lower‑cost, Apple‑integrated solution....
When Steam Reliability Is Non-Negotiable, Hospitals Trust the Miura EX Boiler
The Miura America EX Series dual‑fuel steam boiler delivers full steam in under five minutes, a stark contrast to the hour‑long warm‑up of conventional fire‑tube units. It generates 99%+ saturated steam through a three‑stage separation process, meeting the stringent purity...
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Oricell Therapeutics, a Shanghai‑based biotech, closed a pre‑IPO financing round of more than $110 million to accelerate its CAR‑T programs targeting solid tumors, starting with liver cancer. Its lead candidate, Ori‑C101, targets the GPC3 protein and has shown a 60% response...
Thai Authorities Push for Mandatory Medical Insurance for Scooter Crashes
Thai health officials are considering mandatory medical insurance for tourists who rent scooters, after foreign patients generate roughly $3.1 million in unpaid hospital costs each year. In Phuket alone, Vachira Phuket Hospital reported a $300,000 loss from unpaid treatments, including a...
Navigating the European Union’s AI and Health Data Framework
The EU is consolidating GDPR, the AI Act, and the European Health Data Space (EHDS) into a unified framework that treats health‑focused AI as high‑risk, imposing strict data provenance, validation and post‑deployment oversight. Cross‑border transfers of health data now carry...
Sun Pharma Shares Down 4 per Cent on Reports of Overtures for US-Based Organon
Sun Pharmaceutical Industries’ shares fell about 4% to ₹1,654.70 (≈$20) after media reports that the company is close to a $12 billion bid for U.S. women’s‑health firm Organon. The deal would be Sun’s largest ever acquisition, adding Organon’s $6.2 billion 2025 revenue,...
Vivatides Gets $54M; Wegovy Drops Cold Chain in EU; Gilead Takes Kymera Option
Vivatides Therapeutics announced a $54 million Series A round to accelerate its pre‑clinical siRNA and antisense oligonucleotide programs, with Sequoia Capital leading the investment. In Europe, Novo Nordisk confirmed that its obesity drug Wegovy will drop the costly cold‑chain requirement, simplifying distribution. Meanwhile,...
AHA Names Its Preferred Cybersecurity Provider
The American Hospital Association (AHA) has appointed Rubrik as its Preferred Cybersecurity Provider, giving roughly 5,000 member hospitals access to Rubrik’s cyber‑resilience tools and a breach‑recovery playbook. The designation is part of the AHA’s Preferred Cybersecurity & Risk Provider Program...
Hospital Expenses Grew Twice as Fast as Hospital Prices in 2025, Finds AHA
The American Hospital Association’s 2026 Costs of Caring report shows hospital expenses surged 7.5% in 2025, outpacing price growth by more than double. Workforce costs, which account for about 60% of total spending, rose 5.6%, while supplies and drugs jumped...
The Virtual Pivot: Reformulating Nursing Care Through Remote Health Monitoring
Healthcare leaders are redefining nursing care models by integrating remote patient monitoring (RPM) and telehealth into a hybrid, virtual‑first framework. The "Virtual Pivot" expands nurses’ reach beyond bedside walls, turning surveillance tasks into digital data streams that alert clinicians to...
States' Lawsuit Against HHS Cuts Moves Forward After Court Win
A federal judge in Rhode Island rejected Health and Human Services Secretary Robert F. Kennedy Jr.'s bid to dismiss a lawsuit filed by 19 states and the District of Columbia. The states challenge a March 2025 directive to drastically cut HHS staff and dissolve...
PDUFA and BsUFA Quarterly Hiring Updates
The FDA published its quarterly hiring updates for fiscal years 2023‑2027 under PDUFA VII and BsUFA III. FY2023 staffing was almost complete—CBER filled 99% of its 132 positions and CDER 90% of 77—while FY24 reached only 71% of 79 targeted FTEs. FY25...
FDA/Center for Research on Complex Generics (CRCG) Workshop on Bioequivalence Innovations for Generic Oral Products: Biowaivers, Bridging, and Development for...
On May 5‑6, 2026, the FDA’s Center for Research on Complex Generics hosted a two‑day workshop in Rockville, MD to explore innovative bioequivalence (BE) strategies for generic oral drugs. The agenda covered biowaivers, bridging studies, and development pathways for oncology agents,...
South Africa’s Air Mercy Service Marks 60 Years of Aero-Medical Operations
South Africa’s Air Mercy Service (AMS) marked its 60th anniversary, highlighting six decades of aero‑medical transport, rescue missions, and Flying Doctor outreach for remote communities. Based at Cape Town International Airport, AMS collaborates with government, international partners, and health stakeholders...
Navigating AI Adoption in Healthcare: Insights From HonorHealth's CMIO
HonorHealth’s CMIO Matt Anderson says AI delays jeopardize competitiveness, with 94% of health leaders fearing lost savings. The system relies on a single Epic instance but mixes third‑party tools, especially for ambient workflow improvements. Anderson stresses rigorous ROI measurement—both hard...
Contributor: AI-Based Remote Monitoring for Age-Related Macular Degeneration: Promise, Progress, and Pitfalls
Neovascular age‑related macular degeneration (nAMD) affects roughly 1.5 million Americans and drives over $4 billion in Medicare anti‑VEGF spending. The FDA‑cleared Notal Vision home OCT (hOCT) offers daily AI‑driven retinal scans that could extend injection intervals, but a new cost model shows...
Biotech VCs Ramp up Checks on New Bets After Years of Focusing on Existing Portfolios
Biotech venture capitalists are shifting back to high‑risk, high‑reward investing, with 65% of Q1 2026 capital directed at new startups. Total venture funding in the sector rose to roughly $2.1 billion, up from $1.5 billion a quarter earlier, and average deal size climbed...
Multifaceted Intervention Controls BP in Low-Income Hypertension Patients
The IMPACTS‑BP trial showed that a systematic, team‑based intervention lowered systolic blood pressure by an additional 6.4 mm Hg compared with usual care among low‑income patients in federally qualified health centers in Louisiana and Mississippi. Over 18 months, participants receiving the protocol...
An Implantable Living Pharmacy Produces Drugs in the Body
Scientists from Northwestern, Rice, and Carnegie Mellon unveiled a sub‑cutaneous implant called HOBIT that can synthesize multiple biologic drugs inside the body. The device houses engineered cells in an alginate hydrogel and an electrocatalytic oxygenator that supplies oxygen, enabling sustained...
What’s in a Name? Moderna’s “Vaccine” Vs. “Therapy” Dilemma
Moderna has stopped calling its mRNA melanoma product a "vaccine," rebranding it as an individualized neoantigen therapy (INT) to sidestep growing political resistance to vaccines. The shift follows the cancellation of a $776 million federal bird‑flu vaccine contract and broader skepticism...
Precision Healthcare: How Lean Six Sigma Saves Lives and Dollars
Lean Six Sigma is reshaping U.S. healthcare by streamlining processes, cutting waste, and boosting patient safety. Hospitals that adopted the methodology reported measurable gains: Valley Baptist trimmed surgical turnaround by 15%, handling 1,106 extra cases and adding roughly $1.3 million in...
SVS Quality Initiative Gathers Data to Improve Vascular Care
The Society of Vascular Surgery’s Vascular Quality Initiative (VQI), launched in 2023, now includes more than 7,000 physicians from vascular, cardiothoracic and neurosurgery specialties. Over 900 hospitals and clinics across North America and Singapore have entered data on roughly 1.4 million...
The Perioperative AI Reality Check: Why Hospital Tech Fails Without Clinician Co-Design
Hospital leaders are rushing AI‑powered perioperative tools without clinician input, leading to low adoption and wasted spend. Andrew Fisher, MD, argues that the technology already exists, but success hinges on automating non‑clinical tasks, seamless workflow integration, and co‑design with anesthesiologists,...